The big pharma companies involved in Trump’s new drug pricing program spent over $130 million on lobbying in 2025.

The 17 pharmaceutical companies anchoring TrumpRx, the White House’s new prescription drug-pricing program, poured more than $130 million into federal lobbying in 2025 — a nearly 23% surge that outpaced the broader industry as the plan was being shaped behind the scenes. Those companies accounted for more than a quarter of the record $457.3 million spent on lobbying last year across the…

Source

From Truthout via This RSS Feed.